Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies

Malaria Journal

Research

Michael P. Fay¹  Ruth O. Payne²  Jordan R. Barrett²  Angela M. Minassian²  Simon J. Draper²  Sarah E. Silk²  Ally I. Olotu³  Ababacar Diouf⁴  Carole A. Long⁴  Kazutoyo Miura⁴ 

[1] Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 20852, Rockville, MD, USA;Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU, Oxford, UK;Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania;Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, 20852, Rockville, MD, USA;

关键词: Growth inhibition assay;    RH5;    Plasmodium falciparum;    Vaccine;    Blood-stage;    Precision;   

DOI  :  10.1186/s12936-023-04591-6

 received in 2023-02-14, accepted in 2023-05-16,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundFor blood-stage malaria vaccine development, the in vitro growth inhibition assay (GIA) has been widely used to evaluate functionality of vaccine-induced antibodies (Ab), and Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage antigen. However, precision, also called “error of assay (EoA)”, in GIA readouts and the source of EoA has not been evaluated systematically.MethodsIn the Main GIA experiment, 4 different cultures of P. falciparum 3D7 parasites were prepared with red blood cells (RBC) collected from 4 different donors. For each culture, 7 different anti-RH5 Ab (either monoclonal or polyclonal Ab) were tested by GIA at two concentrations on three different days (168 data points). To evaluate sources of EoA in % inhibition in GIA (%GIA), a linear model fit was conducted including donor (source of RBC) and day of GIA as independent variables. In addition, 180 human anti-RH5 polyclonal Ab were tested in a Clinical GIA experiment, where each Ab was tested at multiple concentrations in at least 3 independent GIAs using different RBCs (5,093 data points). The standard deviation (sd) in %GIA and in GIA50 (Ab concentration that gave 50%GIA) readouts, and impact of repeat assays on 95% confidence interval (95%CI) of these readouts was estimated.ResultsThe Main GIA experiment revealed that the RBC donor effect was much larger than the day effect, and an obvious donor effect was also observed in the Clinical GIA experiment. Both %GIA and log-transformed GIA50 data reasonably fit a constant sd model, and sd of %GIA and log-transformed GIA50 measurements were calculated as 7.54 and 0.206, respectively. Taking the average of three repeat assays (using three different RBCs) reduces the 95%CI width in %GIA or in GIA50 measurements by ~ half compared to a single assay.ConclusionsThe RBC donor effect (donor-to-donor variance on the same day) in GIA was much bigger than the day effect (day-to-day variance using the same donor’s RBC) at least for the RH5 Ab evaluated in this study; thus, future GIA studies should consider the donor effect. In addition, the 95%CI for %GIA and GIA50 shown here help when comparing GIA results from different samples/groups/studies; therefore, this study supports future malaria blood-stage vaccine development.

【 授权许可】

CC BY   
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

【 图 表 】

41116_2023_36_Article_IEq430.gif

41116_2023_36_Article_IEq427.gif

41116_2023_36_Article_IEq426.gif

41116_2023_36_Article_IEq425.gif

41116_2023_36_Article_IEq424.gif

41116_2023_36_Article_IEq423.gif

41116_2023_36_Article_IEq422.gif

41116_2023_36_Article_IEq412.gif

41116_2023_36_Article_IEq359.gif

41116_2023_36_Article_IEq358.gif

Fig. 2

41116_2023_36_Article_IEq354.gif

41116_2023_36_Article_IEq351.gif